ES2196024T3 - Vacunas conjugadas de gangliosido-klh con qs-21. - Google Patents

Vacunas conjugadas de gangliosido-klh con qs-21.

Info

Publication number
ES2196024T3
ES2196024T3 ES94907279T ES94907279T ES2196024T3 ES 2196024 T3 ES2196024 T3 ES 2196024T3 ES 94907279 T ES94907279 T ES 94907279T ES 94907279 T ES94907279 T ES 94907279T ES 2196024 T3 ES2196024 T3 ES 2196024T3
Authority
ES
Spain
Prior art keywords
vaccine
gangliosido
klh
ganglioside
intensify
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94907279T
Other languages
English (en)
Inventor
Philip O Livingston
Friedhelm Helling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Application granted granted Critical
Publication of ES2196024T3 publication Critical patent/ES2196024T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

EL INVENTO PROPORCIONA UNA VACUNA PARA ESTIMULAR O INTENSIFICAR LA PRODUCCION DE UN ANTICUERPO QUE RECONOCE UNA GANGLIOSIDO EN UN SUJETO AL QUE LE ES ADMINISTRADA LA VACUNA. LA VACUNA ESTA COMPUESTA DE UNA CANTIDAD DE GANGLIOSIDO O PORCION OLIGOSACARIDA DE LA MISMA CONJUGADA CON UNA PROTEINA INMUNOGENICA EFICAZ PARA ESTIMULAR O INTENSIFICAR LA PRODUCCION DE ANTICUERPOS EN EL SUJETO. LA VACUNA ESTA ADEMAS COMPUESTA DE UN VEHICULO ADYUVANTE Y FARMACEUTICAMENTE ACEPTABLE. EL INVENTO TAMBIEN PROPORCIONA UN METODO DE USO DE LA VACUNA PARA EL TRATAMIENTO O PREVENCION DE CANCER EN EL QUE LOS GANGLIOSIDOS ESTAN EN LA SUPERFICIE O EN EL ESTROMA DE LAS CELULAS CANCERIGENAS.
ES94907279T 1993-01-22 1994-01-21 Vacunas conjugadas de gangliosido-klh con qs-21. Expired - Lifetime ES2196024T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US926893A 1993-01-22 1993-01-22

Publications (1)

Publication Number Publication Date
ES2196024T3 true ES2196024T3 (es) 2003-12-16

Family

ID=21736616

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94907279T Expired - Lifetime ES2196024T3 (es) 1993-01-22 1994-01-21 Vacunas conjugadas de gangliosido-klh con qs-21.

Country Status (16)

Country Link
US (6) US7014856B1 (es)
EP (2) EP1360963B1 (es)
JP (1) JP3852945B2 (es)
KR (1) KR100307289B1 (es)
AT (2) ATE237357T1 (es)
AU (1) AU685776B2 (es)
CA (1) CA2154488C (es)
DE (2) DE69435025D1 (es)
DK (1) DK0680338T3 (es)
ES (1) ES2196024T3 (es)
FI (1) FI117668B (es)
HK (1) HK1014659A1 (es)
HU (1) HU221420B1 (es)
NO (1) NO318920B1 (es)
NZ (2) NZ261744A (es)
WO (1) WO1994016731A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016731A1 (en) * 1993-01-22 1994-08-04 Sloan-Kettering Institute For Cancer Research Ganglioside-klh conjugate vaccines with qs-21
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5935821A (en) 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
WO1997040140A1 (en) * 1996-04-22 1997-10-30 The Wistar Institute Of Anatomy And Biology Gd2 anti-idiotypic antibodies and uses thereof
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
AUPO732997A0 (en) 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
JP2001517638A (ja) * 1997-09-25 2001-10-09 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 小細胞肺癌に対するフコーシルｇｍ−１−ｋｌｈ接合体ワクチン
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
EP1903114A3 (en) 1997-12-01 2008-07-23 Neose Technologies, Inc. Enzymatic synthesis of gangliosides
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
AU2001248822A1 (en) 2000-04-25 2001-11-07 Otsuka Pharmaceutical Co. Ltd. Gd3-mimetic peptides
EP1731161B1 (en) * 2000-12-22 2014-08-06 Lpath, Inc. Sphingosine-1-phosphate antibodies for the treatment of diseases associated with elevated sphingolipid concentrations
CA2471092A1 (en) 2001-12-21 2003-07-10 Antigenics Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
ATE374788T1 (de) * 2003-08-12 2007-10-15 Lipoxen Technologies Ltd Polysialinsäurederivate
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US20060240047A1 (en) * 2005-01-14 2006-10-26 Avax Technologies, Inc. Method for producing a vaccine for the treatment of cancer
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US20080138334A1 (en) * 2006-05-31 2008-06-12 Sabbadini Roger A Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
US9274129B2 (en) * 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009124294A2 (en) * 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
WO2009132082A2 (en) * 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8512939B2 (en) * 2009-09-25 2013-08-20 Taiwan Semiconductor Manufacturing Company, Ltd. Photoresist stripping technique
JP5977174B2 (ja) * 2010-12-13 2016-08-24 Ｊｃｒファーマ株式会社 スフィンゴ糖脂質の定量法
CN106414472A (zh) * 2013-12-06 2017-02-15 现实制药有限公司 用于靶向癌症和产生抗体的抗神经节苷脂化合物
KR102226248B1 (ko) 2014-06-04 2021-03-12 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
US11786586B2 (en) 2016-12-23 2023-10-17 Aoa Dx Carbohydrate structures and uses thereof
CA3083059A1 (en) * 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin extraction
JP2022535091A (ja) * 2019-06-05 2022-08-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
WO2023212741A1 (en) * 2022-04-29 2023-11-02 Seneb Biosciences, Inc. Treatment of gm1 deficiencies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4591552A (en) * 1982-09-29 1986-05-27 New York Blood Center, Inc. Detection of hepatitis B surface antigen (or antibody to same) with labeled synthetic peptide
US4557931A (en) * 1982-12-02 1985-12-10 Regents Of The University Of California Antigenic compositions and methods for using same
US4652629A (en) * 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5344870A (en) * 1987-12-02 1994-09-06 Alberta Research Council Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5102663A (en) 1988-10-18 1992-04-07 Sloan-Kettering Instutute For Cancer Research Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3
DE3840044A1 (de) 1988-11-27 1990-06-07 Behringwerke Ag Glykosphingolipide mit kopplungsfaehiger gruppe im sphingoidanteil, ihre herstellung und verwendung
GB9001694D0 (en) * 1990-01-25 1990-03-28 Therapeutic Antibodies Inc Immunogenic compositions
WO1994016731A1 (en) * 1993-01-22 1994-08-04 Sloan-Kettering Institute For Cancer Research Ganglioside-klh conjugate vaccines with qs-21
EP0766741A4 (en) 1994-07-07 1998-02-25 Immunex Corp GM-CSF CONTAINED FUSION PROTEINS AND ANTIGENS AND THEIR EXPRESSION IN YEAST

Also Published As

Publication number Publication date
AU685776B2 (en) 1998-01-29
US6916476B1 (en) 2005-07-12
NZ314058A (en) 2000-08-25
NZ261744A (en) 1997-03-24
HU9502201D0 (en) 1995-09-28
EP1360963B1 (en) 2007-09-12
KR960700073A (ko) 1996-01-19
JP3852945B2 (ja) 2006-12-06
FI953529A0 (fi) 1995-07-21
HUT72193A (en) 1996-03-28
CA2154488A1 (en) 1994-08-04
ATE237357T1 (de) 2003-05-15
JPH08508978A (ja) 1996-09-24
NO952914L (no) 1995-09-14
EP1360963A2 (en) 2003-11-12
EP0680338A4 (en) 1997-04-09
FI117668B (fi) 2007-01-15
AU6092494A (en) 1994-08-15
CA2154488C (en) 2009-10-13
NO952914D0 (no) 1995-07-21
EP0680338B1 (en) 2003-04-16
KR100307289B1 (ko) 2001-12-28
EP1360963A3 (en) 2003-12-03
HK1014659A1 (en) 1999-09-30
HU221420B1 (en) 2002-09-28
DE69432513T2 (de) 2003-12-24
US20060153859A1 (en) 2006-07-13
NO318920B1 (no) 2005-05-23
US6936253B1 (en) 2005-08-30
US7001601B1 (en) 2006-02-21
EP0680338A1 (en) 1995-11-08
US6967022B1 (en) 2005-11-22
FI953529A (fi) 1995-09-15
ATE372783T1 (de) 2007-09-15
DK0680338T3 (da) 2003-07-21
US7014856B1 (en) 2006-03-21
DE69435025D1 (de) 2007-10-25
DE69432513D1 (de) 2003-05-22
WO1994016731A1 (en) 1994-08-04

Similar Documents

Publication Publication Date Title
ES2196024T3 (es) Vacunas conjugadas de gangliosido-klh con qs-21.
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
EA199800946A1 (ru) Концентрированный препарат антител
ES2164251T3 (es) Vacuna que comprende un conjugado antigeno polisacarido-proteina transportadora y proteina transportadora libre.
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
ES2134797T3 (es) Peptidos y fragmentos de peptidos terapeuticamente utiles.
CO5280094A1 (es) Un analogo de a o app y una composicion inmunogenica que comprende dicho analogo
FI946173A0 (fi) Menetelmä lääkeaineiden antotehon parantamiseksi muunnettujen saponiinien avulla
ATE114160T1 (de) Immunogenische zusammensetzungen gegen gastrin- peptide.
PT90727A (pt) Processo para a preparacao de uma proteina possuindo um ou mais determinantes imuno-reactivos e/ou antigenicos de um antigenio de superficie eimeria e de vacinas contra a coccidiose que a contem
AR008799A1 (es) Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento
BR9610679A (pt) Antígenos de leishmania para uso na terapia e disgnose da leishmaniose
ATE255905T1 (de) Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält
EE9800182A (et) PGE-1 sisaldavad lüofiliseeritud liposoomid kasutamiseks erektsioonihäire ravis
ES2079851T3 (es) Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas.
ATE88350T1 (de) Arzneimittel.
ITRM930154A0 (it) Uso di terbinafina per il trattamento terapeutico della pneumocistosi.
UA42741C2 (uk) Пептид маститної вакцини (варіанти), пептид складного антигенного представлення (варіанти), фармацевтична композиція (варіанти)
ES2101311T3 (es) Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer.
EP0293333A3 (en) A synthetic nonapeptide of use as an adjuvant
DE69322960D1 (de) Empfängnisverhütender impfstoff
ES2151489T3 (es) Procedimiento y composicion para el tratamiento de trastornos relacionados con herpes.
IT8821666A0 (it) Coniugato peptidico immunologicamente attivo utile come vaccino antimalaria e metodo di immunizzazione impiegante lo stesso
IT8847913A0 (it) Uso di enalapril nel trattamento terapeutico delle cefalee essenziali
ITRM940453A1 (it) "uso della proteina p1lsa per la preparazione di un medicamento da utilizzarsi nella terapia di patologie indotte da danni cellulari da